• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

LL37 might promote local invasion of melanoma by the stimulation of melanoma cells and tumor-associated macrophages

Research Project

Project/Area Number 20K17337
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 53050:Dermatology-related
Research InstitutionTohoku University

Principal Investigator

Kambayashi Yumi  東北大学, 医学系研究科, 助教 (50755303)

Project Period (FY) 2020-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2021: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywordsメラノーマ / LL37 / MMP1 / MMP9 / IL-23p19 / 重複型血管新生 / 発芽型血管新生 / 悪性黒色腫 / 腫瘍随伴性マクロファージ / IL-17 / 局所浸潤 / 血管新生因子 / 腫瘍随伴性マクロファージ(TAMs) / 芳香族炭化水素受容体(AhR) / 炎症性サイトカイン
Outline of Research at the Start

悪性黒色腫の発症には、紫外線が関与していること知られている。しかし、紫外線が悪性黒色腫の腫瘍免疫環境に与える影響については明らかにされていない。紫外線によって皮膚で誘導される芳香族炭化水素受容体(Aryl hydrocarbon receptor: AhR)を介した経路は、上皮系皮膚悪性腫瘍の進展に関与することから、この経路に着目して、紫外線が悪性黒色腫の腫瘍免疫環境に及ぼす影響を検証し、発癌のメカニズムを解明する。

Outline of Final Research Achievements

LL37 stimulates tumor-associate macrophage (TAMs) to recruit immunosuppressive cells in tumor microenvironment, leading to tumor progression. Since tumor (T) stage is determined by the vertical invasion of tumor cells in melanoma, we hypothesized LL37 expression level might correlate with the T stage in melanoma patients. To determine pro-angiogenetic factors by LL37 stimulation in melanoma, we used B16F10 melanoma model in vivo.We administered CRAMP (mouse LL37). Intra-tumoral administered CRAMP significantly increased the mRNA expression of p19, MMP1a and MMP9 in B16F10 melanoma. To further confirm the induction of pro-angiogenic factors in melanoma, we stimulated A375 and G361 human melanoma cells by LL37 in vitro. The mRNA expression of p19 and MMP9, but not MMP1, was significantly increased by the stimulation of LL37. Correctively, these results suggested that LL37 stimulates both tumor cells and TAMs to promote the invasion of melanoma by the induction of pro-angiogenic factors.

Academic Significance and Societal Importance of the Research Achievements

本研究によりLL37はメラノーマ細胞側では主に重複型血管新生と繊維化に、TAMsには局所コラーゲン融解による局所浸潤と発芽型血管新生に関与することが明らかとなり、メラノーマの腫瘍局所浸潤のメカニズムが明らかとなった。今後、本研究で明らかになった血管新生因子をターゲットとした治療の開発を進めることにより、今後、メラノーマの局所進行を抑制する薬剤の開発が進むことにより、欧米に比べて明らかに局所浸潤転移の多い本邦のメラノーマ患者の進行抑制の一助になり、さらには進行期で現在年間数千万円の医療費を削減することが可能となる。以上から長期的には医療費削減の一助となる可能性がある。

Report

(3 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • Research Products

    (35 results)

All 2022 2021 2020

All Journal Article (22 results) (of which Peer Reviewed: 22 results,  Open Access: 3 results) Presentation (13 results)

  • [Journal Article] Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy2022

    • Author(s)
      Ohuchi Kentaro、Amagai Ryo、Tamabuchi Erika、Kambayashi Yumi、Fujimura Taku
    • Journal Title

      The Journal of Dermatology

      Volume: - Issue: 5

    • DOI

      10.1111/1346-8138.16304

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Nodal anaplastic large cell lymphoma with lymphomatoid papulosis following treatment of initially presumed atopic dermatitis with dupilumab: A case report2021

    • Author(s)
      Amagai Mayuko、Ozawa Maki、Amagai Ryo、Ohuchi Kentaro、Muto Yusuke、Kambayashi Yumi、Aiba Setsuya、Fujimura Taku
    • Journal Title

      Dermatologic Therapy

      Volume: 35 Issue: 3

    • DOI

      10.1111/dth.15290

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Successful treatment of BRAF/MEK inhibitor‐resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity‐modulated radiotherapy2021

    • Author(s)
      Okuma Takami、Furudate Sadanori、Kambayashi Yumi、Hashimoto Akira、Aiba Setsuya、Fujimura Taku
    • Journal Title

      The Journal of Dermatology

      Volume: 48 Issue: 9 Pages: 1419-1422

    • DOI

      10.1111/1346-8138.15962

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas2021

    • Author(s)
      Fujimura Taku、Amagai Ryo、Kambayashi Yumi、Aiba Setsuya
    • Journal Title

      Pharmaceutics

      Volume: 13 Issue: 2 Pages: 200-200

    • DOI

      10.3390/pharmaceutics13020200

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Dabrafenib plus trametinib combination therapy triggered onset of pustulosis palmaris et plantaris in a patient with advanced cutaneous melanoma2021

    • Author(s)
      Muto Yusuke、Fujimura Taku、Kambayashi Yumi、Ohuchi Kentaro、Amagai Ryo、Okuma Takami、Furudate Sadanori、Hashimoto Akira、Aiba Setsuya
    • Journal Title

      The Journal of Dermatology

      Volume: 48 Issue: 3

    • DOI

      10.1111/1346-8138.15747

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma2020

    • Author(s)
      Fujimura Taku、Tanita Kayo、Ohuchi Kentaro、Sato Yota、Lyu Chunbing、Kambayashi Yumi、Fujisawa Yasuhiro、Tanaka Ryota、Hashimoto Akira、Aiba Setsuya
    • Journal Title

      Melanoma Research

      Volume: 30 Issue: 6 Pages: 613-618

    • DOI

      10.1097/cmr.0000000000000685

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma2020

    • Author(s)
      Amagai Ryo、Fujimura Taku、Muto Yusuke、Kambayashi Yumi、Furudate Sadanori、Ohuchi Kentaro、Okuma Takami、Hashimoto Akira、Aiba Setsuya
    • Journal Title

      Dermatologic Therapy

      Volume: 34 Issue: 1

    • DOI

      10.1111/dth.14544

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Erythema nodosum developed in a patient with advanced cutaneous melanoma treated with dabrafenib plus trametinib combination therapy2020

    • Author(s)
      Muto Yusuke、Fujimura Taku、Kambayashi Yumi、Ohuchi Kentaro、Amagai Ryo、Okuma Takami、Furudate Sadanori、Hashimoto Akira、Aiba Setsuya
    • Journal Title

      Dermatologic Therapy

      Volume: 33 Issue: 6

    • DOI

      10.1111/dth.14430

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock2020

    • Author(s)
      Muto Yusuke、Fujimura Taku、Kambayashi Yumi、Ohuchi Kentaro、Amagai Ryo、Hashimoto Akira、Aiba Setsuya
    • Journal Title

      Case Reports in Oncology

      Volume: 13 Issue: 3 Pages: 1141-1144

    • DOI

      10.1159/000510261

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Treatment of Advanced Melanoma: Past, Present and Future2020

    • Author(s)
      Fujimura Taku、Kambayashi Yumi、Ohuchi Kentaro、Muto Yusuke、Aiba Setsuya
    • Journal Title

      Life

      Volume: 10 Issue: 9 Pages: 208-208

    • DOI

      10.3390/life10090208

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Successful treatment of CCR4 + mycosis fungoides palmaris et plantaris with mogamulizumab monotherapy2020

    • Author(s)
      Fujimura Taku、Kambayashi Yumi、Ohuchi Kentaro、Amagai Ryo、Muto Yusuke、Aiba Setsuya
    • Journal Title

      Dermatologic Therapy

      Volume: 33 Issue: 4

    • DOI

      10.1111/dth.13731

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy2020

    • Author(s)
      Fujimura Taku、Kambayashi Yumi、Tono Hisayuki、Lyu Chinbing、Ohuchi Kentaro、Hashimoto Akira、Aiba Setsuya
    • Journal Title

      Dermatologic Therapy

      Volume: 33 Issue: 4

    • DOI

      10.1111/dth.13672

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study2020

    • Author(s)
      Fujisawa Y.、Fujimura T.、Matsushita S.、Yamamoto Y.、Uchi H.、Otsuka A.、Funakoshi T.、Miyagi T.、Hata H.、Gosho M.、Kambayashi Y.、Aoki M.、Yanagi T.、Ohira A.、Nakamura Y.、Maeda T.、Yoshino K.
    • Journal Title

      British Journal of Dermatology

      Volume: 183 Issue: 5 Pages: 831-839

    • DOI

      10.1111/bjd.19042

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Successful treatment of mogamulizumab‐resistant mycosis fungoides with mogamulizumab plus etoposide combined therapy: Investigation of the immunomodulatory effects of etoposide on the tumor microenvironment2020

    • Author(s)
      Ohuchi Kentaro、Fujimura Taku、Kambayashi Yumi、Amagai Ryo、Lyu Chunbing、Tanita Kayo、Sato Yota、Aiba Setsuya
    • Journal Title

      Dermatologic Therapy

      Volume: 33 Issue: 4

    • DOI

      10.1111/dth.13487

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy2020

    • Author(s)
      Kambayashi Yumi、Fujimura Taku、Kuroda Hiroshi、Otsuka Atsushi、Irie Hiroyuki、Aiba Setsuya
    • Journal Title

      Case Reports in Oncology

      Volume: 13 Issue: 1 Pages: 474-477

    • DOI

      10.1159/000506976

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] IL-23 Expression in Stewart-Treves Syndrome: Two Case Reports and Immunohistochemical Investigation2020

    • Author(s)
      Yoshida Saaya、Fujimura Taku、Ohuchi Kentaro、Kambayashi Yumi、Segawa Yuichiro、Yamazaki Emi、Tono Hisayuki、Takahashi Toshiya、Tsuchiyama Kenichiro、Aiba Setsuya
    • Journal Title

      Case Reports in Oncology

      Volume: 13 Issue: 1 Pages: 462-467

    • DOI

      10.1159/000506975

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Case series of BRAF ‐mutated advanced melanoma treated with encorafenib plus binimetinib combination therapy2020

    • Author(s)
      Fujimura Taku、Yoshino Koji、Kato Hiroshi、Fujisawa Yasuhiro、Nakamura Yoshiyuki、Yamamoto Yuki、Kunimoto Kayo、Ito Takamichi、Matsushita Shigeto、Maekawa Takeo、Ohuchi Kentaro、Amagai Ryo、Muto Yusuke、Furudate Sadanori、Kambayashi Yumi、Hashimoto Akira、Aiba Setsuya
    • Journal Title

      The Journal of Dermatology

      Volume: 48 Issue: 3 Pages: 397-400

    • DOI

      10.1111/1346-8138.15688

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Severe pyrexia from nivolumab‐resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib2020

    • Author(s)
      Amagai Ryo、Fujimura Taku、Kambayashi Yumi、Sato Yota、Tanita Kayo、Ohuchi Kentaro、Hashimoto Akira、Aiba Setsuya
    • Journal Title

      The Journal of Dermatology

      Volume: 47 Issue: 6 Pages: 654-657

    • DOI

      10.1111/1346-8138.15346

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy2020

    • Author(s)
      Fujimura Taku、Kambayashi Yumi、Ohuchi Kentaro、Amagai Ryo、Sato Yota、Tanita Kayo、Hashimoto Akira、Aiba Setsuya
    • Journal Title

      Case Reports in Oncology

      Volume: 13 Issue: 1 Pages: 271-275

    • DOI

      10.1159/000506327

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy2020

    • Author(s)
      Fujimura Taku、Sato Yota、Tanita Kayo、Amagai Ryo、Shimauchi Takatoshi、Ogata Dai、Fukushima Satoshi、Miyashita Azusa、Fujisawa Yasuhiro、Kambayashi Yumi、Aiba Setsuya
    • Journal Title

      The Journal of Dermatology

      Volume: - Issue: 6 Pages: 636-640

    • DOI

      10.1111/1346-8138.15322

    • Related Report
      2020 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used2020

    • Author(s)
      Ogata Dai、、、Kambayashi Yumi、Yoshikawa Syusuke、Yamazaki Naoya、Tsuchida Tetsuya
    • Journal Title

      European Journal of Cancer

      Volume: 127 Pages: 108-117

    • DOI

      10.1016/j.ejca.2019.12.018

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Journal Article] Immune checkpoint inhibitor‐induced vitiligo in advanced melanoma could be related to increased levels of CCL192020

    • Author(s)
      Fujimura T.、Tanita K.、Sato Y.、Lyu C.、Kambayashi Y.、Fujisawa Y.、Uchi H.、Yamamoto Y.、Otsuka A.、Yoshino K.、Matsushita S.、Funakoshi T.、Fukushima S.、Hata H.、Hashimoto A.、Aiba S.
    • Journal Title

      British Journal of Dermatology

      Volume: 182 Issue: 5 Pages: 1297-1300

    • DOI

      10.1111/bjd.18721

    • Related Report
      2020 Research-status Report
    • Peer Reviewed
  • [Presentation] 筋肉内転移をきたしたイマチニブで治療した隆起性皮膚線維肉腫の1例2021

    • Author(s)
      神林由美、藤村卓、天貝諒、遠野久幸、相場節也、笠原佑記、綿貫宗則
    • Organizer
      第37回日本皮膚悪性腫瘍学会学術大会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 当科で使用した根治切除不能の悪性黒色腫に対するBRAF+MEK阻害剤併用の使用経験2021

    • Author(s)
      大熊崇生、藤村卓、神林由美、古舘禎騎、武藤雄介、大内謙太郎、天貝諒、千葉広夢、橋本彰、相場節也
    • Organizer
      第37回日本皮膚悪性腫瘍学会学術大会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 進行期悪性黒色腫に対して免疫チェックポイント阻害剤投与により完全奏功を達成した後に休薬を行った4例2021

    • Author(s)
      武藤雄介、藤村卓、神林由美、古舘禎騎、大内謙太郎、天貝諒、千葉広夢、大熊崇生、橋本彰、相場節也
    • Organizer
      第37回日本皮膚悪性腫瘍学会学術大会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 進行期悪性黒色腫における抗PD1抗体とのTM5614の安全性・有効性を検討する第II相試験2021

    • Author(s)
      藤村卓、藤澤康弘、吉野公二、大塚篤司、松下茂人、神林由美、武藤雄介、大内謙太郎、橋本彰、相場節也
    • Organizer
      第120回日本皮膚科学会総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 根治切除不能悪性黒色腫における抗PD1抗体治療効果と従来予測因子との相関性の検証2021

    • Author(s)
      藤村 卓, 谷田 佳世, 佐藤 遥太, 神林 由美, 藤澤 康弘, 内 博史, 山本 有紀, 大塚 篤司, 吉野 公二, 相場 節也
    • Organizer
      第36回 日本皮膚悪性腫瘍学会学術大会
    • Related Report
      2020 Research-status Report
  • [Presentation] モガムリズマブ単剤療法無効例にエトポシド療法が著効した皮膚T細胞リンパ腫の3例2021

    • Author(s)
      大内 謙太郎, 藤村 卓, 神林 由美, 天貝 諒, 佐藤 遥太, 谷田 佳世, 相場 節也
    • Organizer
      第36回 日本皮膚悪性腫瘍学会学術大会
    • Related Report
      2020 Research-status Report
  • [Presentation] ゲノムパネルで新規治療のターゲットを発見した進行期悪性黒色腫の1例2021

    • Author(s)
      神林 由美, 藤村 卓, 浅野 雅之, 橋本 彰, 相場 節也, 城田 英和
    • Organizer
      第36回 日本皮膚悪性腫瘍学会学術大会
    • Related Report
      2020 Research-status Report
  • [Presentation] 東北大学における進行期悪性黒色腫に対する抗PD-1抗体を用いた術後補助療法2020

    • Author(s)
      天貝 諒, 藤村 卓, 神林 由美, 大内 謙太郎, 佐藤 遥太, 谷田 佳世, 遠野 久幸, 橋本 彰, 相場 節也
    • Organizer
      第36回 日本皮膚悪性腫瘍学会学術大会
    • Related Report
      2020 Research-status Report
  • [Presentation] 東北大学におけるニボルマブ+イピリムマブ併用療法の使用経験2020

    • Author(s)
      大内 謙太郎, 藤村 卓, 神林 由美, 佐藤 遥太, 谷田 佳世, 天貝 諒, 橋本 彰, 相場 節也
    • Organizer
      第119回 日本皮膚科学会総会
    • Related Report
      2020 Research-status Report
  • [Presentation] ベキサロテンにより治療した皮膚T細胞性リンパ腫 32例の多施設共同後ろ向き解析2020

    • Author(s)
      佐藤 遥太, 藤村 卓, 神林 由美, 緒方 大, 島内 隆寿, 藤澤 康弘, 福島 聡, 天貝 諒, 谷田 佳世, 相場 節也
    • Organizer
      第119回 日本皮膚科学会総会
    • Related Report
      2020 Research-status Report
  • [Presentation] Encorafenib/Binimetinib併用療法によりスパイク熱を生じた3例 発症関連因子の検討2020

    • Author(s)
      天貝 諒, 藤村 卓, 神林 由美, 佐藤 遥太, 大内 謙太郎, 橋本 彰, 相場 節也
    • Organizer
      第119回 日本皮膚科学会総会
    • Related Report
      2020 Research-status Report
  • [Presentation] 抗PD1抗体治療に伴う白斑と治療効果の相関性の検証2020

    • Author(s)
      藤村 卓, 谷田 佳世, 佐藤 遥太, 神林 由美, 藤澤 康弘, 内 博史, 山本 有紀, 大塚 篤司, 吉野 公二, 相場 節也
    • Organizer
      第119回 日本皮膚科学会総会
    • Related Report
      2020 Research-status Report
  • [Presentation] 東北大学で経験したエンコラフェニブ、ビニメチニブ併用療法で加療した進行期悪性黒色腫の6例2020

    • Author(s)
      大内 謙太郎, 藤村 卓, 天貝 諒, 佐藤 遥太, 谷田 佳世, 玉渕 恵里佳, 神林 由美, 橋本 彰, 相場 節也
    • Organizer
      第84回  日本皮膚科学会東部支部学術大会
    • Related Report
      2020 Research-status Report

URL: 

Published: 2020-04-28   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi